Heparin cofactor II‐thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short‐ and long‐term treatment effects in mucopolysaccharide diseases
Open Access
- 18 December 2010
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 34 (2), 499-508
- https://doi.org/10.1007/s10545-010-9254-8
Abstract
Early detection of mucopolysaccharidosis (MPS) is an important factor in treatment success; therefore, good disease biomarkers are vital. We evaluate heparin cofactor II-thrombin complex (HCII-T) as a biomarker in serum and dried blood spots (DBS) of MPS patients. Serum HCII-T and urine dermatan sulphate:chondroitin sulphate (DS:CS) ratio are also compared longitudinally against clinical outcomes in MPSI, II and VI patients following treatment. Samples were collected from MPS patients at the Royal Manchester Children's Hospital. DS:CS ratio was obtained by measuring the area density of spots from 2D electrophoresis of urinary glycosaminoglycans. Serum and DBS HCII-T was measured by sandwich ELISA. Serum HCII-T is elevated approximately 25-fold in MPS diseases that store DS, clearly distinguishing untreated MPSI, II and VI patients from unaffected age-matched controls. Serum HCII-T is also elevated in MPSIII, which leads to storage of heparan sulphate, with an increase of approximately 4-fold over unaffected age-matched controls. Urine DS:CS ratio and serum HCII-T decrease in response to treatment of MPSI, II and VI patients. HCII-T appears to respond rapidly to perturbations in treatment, whilst DS:CS ratio responds more slowly. HCII-T is a suitable biomarker for MPSI, II and VI, and it may also be informative for MPS diseases storing HS alone, such as MPSIII, although the elevation observed is smaller. In treated MPS patients, HCII-T and DS:CS ratio appear to measure short-term and long-term treatment outcomes, respectively. The potential value of HCII-T measurement in DBS for newborn screening of MPS diseases warrants further investigation.Keywords
Funding Information
- National Institute on Handicapped Research
This publication has 25 references indexed in Scilit:
- Circadian rhythm and suprachiasmatic nucleus alterations in the mouse model of mucopolysaccharidosis IIIBBehavioural Brain Research, 2010
- Evaluation of heparin cofactor II–thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB miceMolecular Genetics and Metabolism, 2010
- Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type IIActa Paediatrica, 2008
- International Morquio A Registry: Clinical manifestation and natural course of Morquio A diseaseJournal of Inherited Metabolic Disease, 2007
- Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic diseaseBone Marrow Transplantation, 2007
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004
- Lysosomal storage disorders: emerging therapeutic options require early diagnosisEuropean Journal of Pediatrics, 2003
- Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutationBone Marrow Transplantation, 1998
- Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centresArchives of Disease in Childhood, 1997
- Bone-Marrow Transplantation in the Maroteaux–Lamy Syndrome (Mucopolysaccharidosis Type VI)The New England Journal of Medicine, 1984